08.04.2014 20:29:00
|
Eli Lilly and Company -- Moody's: Actos ruling is credit negative for Eli Lilly
New York, April 08, 2014 -- Moody's Investors Service commented that a federal jury award in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc. is credit-negative for Eli Lilly and Company ("Lilly"). Lilly is rated A2/Prime-1 with a stable rating outlook. There is no impact on Lilly's rating or outlook arising from the jury award.